摘要
目前,除了已被FDA批准的普鲁士蓝、Ca/Zn-DTPA和碘化钾等放射性核素促排剂,还有几类放射性核素促排剂如二乙基三胺五乙酸(diethylene triamine pentacetate acid,DTPA)口服制剂、铁载体类似物、羟吡啶酮类螯合剂、酚性聚氨基羧酸盐衍生物、两亲性口服螯合剂、壳聚糖及其相关衍生物、纳米吸附剂、二膦酸盐类配体等正处于研发阶段,其中DTPA口服制剂发展较快,有较好的研发前景。本文将对已被FDA批准的和这些处于正在研发阶段的放射性核素促排剂进行详细介绍。
At present,Prussian blue,Ca /Zn-DTPA and potassium iodide radionuclide chelating agents have been approved by FDA. In addition,several kinds of radionuclide chelating agents are in the developing stage,such as DTPA oral preparations,iron carrier analogues,hydroxyl pyridine ketone chelating agent,phenol polyaminocarboxylate derivatives,amphiphilic oral chelating agent,chitosan and its related derivatives,nanoadsorbent,and two phosphonic acid salt ligands. The development of DTPA oral preparations is faster,having a good development prospect. In this article,we introduced radionuclide chelating agents,both having been approved by FDA and being in the developing stage,in detail.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2016年第21期2446-2449,共4页
Chinese Journal of New Drugs
基金
福建省自然科学基金(2015J01342)
关键词
放射性核素
促排剂
核辐射
二乙基三胺五乙酸
radioactive nuclide
chelating agents
nuclear radiation
diethylene triamine pentacetate acid
